参考文献/References:
[1] Wechalekar AD,Gillmore JD,Hawkins PN. Systemic amyloidosis[J]. Lancet,2016,387(10038):2641-2654.
[2] Bloom MW,Gorevic PD. Cardiac amyloidosis[J]. Ann Intern Med,2023,176(3):Itc33-itc48.
[3] Merlini G,Dispenzieri A,Sanchorawala V,et al. Systemic immunoglobulin light chain amyloidosis[J]. Nature reviews Disease primers,2018,4(1):38.
[4] Baker KR. Light chain amyloidosis:epidemiology,staging,and prognostication[J]. Methodist Debakey Cardiovasc J,2022,18(2):27-35.
[5] Arnold JR,Mccann GP. Cardiovascular magnetic resonance:applications and practical considerations for the general cardiologist[J]. Heart,2020,106(3):174-181.
[6] Aimo A,Merlo M,Porcari A,et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies[J]. Eur J Heart Fail,2022,24(12):2342-2351.
[7] Arenja N,Andre F,Riffel JH,et al. Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis[J]. J Cardiovasc Magn Reson,2019,21(1):53.
[8] Miao FJ,Tang CX,Chen WC,et al. [The prognostic value of morphological and functional parameters of cardiac magnetic resonance in patients with systemic light chain amyloidosis][J]. Zhonghua yi xue za zhi,2023,103(7):506-512.
[9] Mohty D,Boulogne C,Magne J,et al. Prognostic value of left atrial function in systemic light-chain amyloidosis:a cardiac magnetic resonance study[J]. Eur Heart J Cardiovasc Imaging,2016,17(9):961-969.
[10] Ochs MM,Fritz T,Arenja N,et al. Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis[J]. J Cardiovasc Magn Reson,2017,19(1):87.
[11] Xu J,Yang W,Zhao S,et al. State-of-the-art myocardial strain by CMR feature tracking:clinical applications and future perspectives[J]. Eur Radiol,2022,32(8):5424-5435.
[12] Illman JE,Arunachalam SP,Arani A,et al. MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis[J]. Amyloid,2018,25(2):101-108.
[13] Wan K,Sun J,Yang D,et al. Left ventricular myocardial deformation on cine MR images: relationship to severity of disease and prognosis in light-chain amyloidosis[J]. Radiology,2018,288(1):73-80.
[14] Lu J,Yang Z,Tang D,et al. The correlation of left atrial dysfunction and amyloid load in patients with immunoglobulin light-chain cardiac amyloidosis:a 3T cardiac magnetic resonance study[J]. Br J Radiol,2023,96(1148):20220985.
[15] Tan Z,Yang Y,Wu X, et al. Left atrial remodeling and the prognostic value of feature tracking derived left atrial strain in patients with light-chain amyloidosis:a cardiovascular magnetic resonance study[J]. Int J Cardiovasc Imaging,2022,38(7):1519-1532.
[16] Wan K,Lin J,Guo X,et al. Prognostic value of right ventricular dysfunction in patients with al amyloidosis:comparison of different techniques by cardiac magnetic resonance[J]. J Magn Reson Imaging,2020,52(5):1441-1448.
[17] Li X,Li J,Lin L,et al. Left and right ventricular myocardial deformation and late gadolinium enhancement:incremental prognostic value in amyloid light-chain amyloidosis[J]. Cardiovascular diagnosis and therapy,2020,10(3):470-480.
[18] Duca F,Snidat A,Binder C,et al. Hemodynamic profiles and their prognostic relevance in cardiac amyloidosis[J]. J C lin Med,2020,9(4):1093.
[19] Ricci F,Barison A,Todiere G,et al. Prognostic value of pulmonary blood volume by first-pass contrast-enhanced CMR in heart failure outpatients:the PROVE-HF study[J]. Eur Heart J Cardiovasc Imaging,2018,19(8):896-904.
[20] Houard L,Amzulescu MS,Colin G,et al. Prognostic value of pulmonary transit time by cardiac magnetic resonance on mortality and heart failure hospitalization in patients with advanced heart failure and reduced ejection fraction[J]. Circ Cardiovasc Imaging,2021,14(1):e011680.
[21] Seraphim A,Knott KD,Menacho K,et al. Prognostic value of pulmonary transit time and pulmonary blood volume estimation using myocardial perfusion?CMR[J]. JACC Cardiovasc Imaging,2021,14(11):2107-2119.
[22] Bi K,Wan K,Xu Y,et al. Pulmonary transit time derived from first-pass perfusion cardiac mr imaging:a potential new marker for cardiac involvement and prognosis in light-chain amyloidosis[J]. J Magn Reson Imaging,2023.DOI:10.1002/jmri.29135.
[23] Markousis-Mavrogenis G,Giannakopoulou A,Belegrinos A,et al. Cardiovascular magnetic resonance imaging patterns in rare cardiovascular diseases[J]. J C lin Med,2022,11(21):6403.
[24] Dohy Z,Szabo L,Pozsonyi Z,et al. Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis[J]. PLoS One,2022,17(6):e0269807.
[25] Wan K,Sun J,Han Y,et al. Right ventricular involvement evaluated by cardiac magnetic resonance imaging predicts mortality in patients with light chain amyloidosis[J]. Heart Vessels,2018,33(2):170-179.
[26] Boynton SJ,Geske JB,Dispenzieri A,et al. LGE provides incremental prognostic information over?serum biomarkers in AL?cardiac?amyloidosis[J]. JACC Cardiovasc Imaging,2016,9(6):680-686.
[27] Lin L,Li X,Feng J,et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis[J]. J Cardiovasc Magn Reson,2018,20(1):2.
[28] Dungu JN,Valencia O,Pinney JH,et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2014,7(2):133-142.
[29] Wan K,Sun J,Han Y,et al. Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis[J]. Circ J,2018,82(3):739-746.
[30] Liu Y,Zhu J,Chen M,et al. 3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis[J]. Annals of translational medicine,2022,10(14):794.
[31] Maggialetti N,Torrente A,Lorusso G,et al. Role of cardiovascular magnetic resonance in cardiac amyloidosis:a narrative review[J]. J Pers Med,2024,14(4):407.
[32] Banypersad SM,Fontana M,Maestrini V,et al. T1 mapping and survival in systemic light-chain amyloidosis[J]. Eur Heart J,2015,36(4):244-251.
[33] Miao F,Tang C,Ren G,et al. The prognostic value of multiparametric cardiac magnetic resonance in patients with systemic light chain amyloidosis[J]. Front Oncol,2023,13:1069788.
[34] Wan K,Li W,Sun J,et al. Regional amyloid distribution and impact on mortality in light-chain amyloidosis:a T1 mapping cardiac magnetic resonance study[J]. Amyloid,2019,26(1):45-51.
[35] Martinez-Naharro A,Patel R,Kotecha T,et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment[J]. Eur Heart J,2022,43(45):4722-4735.
[36] Ioannou A,Patel RK,Martinez-Naharro A,et al. Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping[J]. JAMA Cardiol,2023,8(9):848-852.
[37] Grazzini G,Pradella S,Bani R,et al. The role of T2 mapping in cardiac amyloidosis[J]. Diagnostics (Basel, Switzerland),2024,14(10):1048.
[38] Kotecha T,Martinez-Naharro A,Treibel TA,et al. Myocardial edema and prognosis in?amyloidosis[J]. J Am Coll Cardiol,2018,71(25):2919-2931.
[39] Ridouani F,Damy T,Tacher V,et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis[J]. J Cardiovasc Magn Reson,2018,20(1):58.
[40] Polidori T,De Santis D,Rucci C,et al. Radiomics applications in cardiac imaging:a comprehensive review[J]. Radiol Med,2023,128(8):922-933.
[41] Zhou XY,Tang CX,Guo YK,et al. Late gadolinium enhanced cardiac MR derived radiomics approach for predicting all-cause mortality in cardiac amyloidosis:a multicenter study[J]. Eur Radiol,2024;34(1):402-410.
相似文献/References:
[1]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(8):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[2]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[3]徐源蔚 陈玉成.心脏磁共振在检测自身免疫性风湿疾病心脏受累中的应用进展[J].心血管病学进展,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
XU Yuanwei,CHEN Yucheng.Advances in the Application of Cardiac Magnetic Resonance in Detecting Cardiac Involvement in Autoimmune Rheumatic Disease[J].Advances in Cardiovascular Diseases,2019,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
[4]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(8):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[5]冯泽豪 姜萌 卜军.心脏磁共振评价化疗所致心肌损伤的研究进展[J].心血管病学进展,2019,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
FENG Zehao,JIANG Meng,PU Jun.Cardiovascular Magnetic Resonance for Detection of Myocardial Impairments Caused by Chemotherapy[J].Advances in Cardiovascular Diseases,2019,(8):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
[6]金荣杰 徐勇 邓珏琳 沈明志.应用心脏磁共振评估前列地尔对ST段抬高型心肌梗死患者心肌灌注的影响[J].心血管病学进展,2020,(10):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
JIN RongjieXU YongDENG JuelinSHEN Mingzhi.Effect of Alprostadil on Myocardial Perfusion of Patients with ST Segment Elevation Myocardial Infarction Directly Receiving Percutaneous Coronary Intervention Assessed with Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(8):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
[7]张宁 王嫱.心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展[J].心血管病学进展,2020,(11):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
ZHANG Ning,WANG Qiang.Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(8):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
[8]陈小玲 陈玉成.肺高压心肌纤维化磁共振评价及临床意义[J].心血管病学进展,2021,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
CHEN Xiaoling,CHEN Yucheng.Cardiac Magnetic Resonance Evaluation and the Clinical Value of Myocardial Fibrosis in Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2021,(8):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
[9]尹丽丹 蒲守芳 何娟 陈玉成.右心室评价方法及其临床应用[J].心血管病学进展,2021,(6):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]
YIN Lidan,PU Shoufang,HE Juan,et al.The Methods to Evaluation of Right Ventricular and its Clinical Application[J].Advances in Cardiovascular Diseases,2021,(8):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]
[10]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(8):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]